WINTON GROUP Ltd Decreases Position in Insulet Co. (NASDAQ:PODD)

WINTON GROUP Ltd cut its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 56.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,135 shares of the medical instruments supplier's stock after selling 5,353 shares during the period. WINTON GROUP Ltd's holdings in Insulet were worth $1,080,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of PODD. Baillie Gifford & Co. grew its position in Insulet by 3.5% in the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock valued at $614,998,000 after acquiring an additional 79,982 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Insulet by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock valued at $403,339,000 after purchasing an additional 22,850 shares in the last quarter. Artisan Partners Limited Partnership increased its position in Insulet by 24.1% during the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after purchasing an additional 149,524 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Insulet by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier's stock valued at $168,902,000 after purchasing an additional 10,694 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in Insulet by 7.6% in the fourth quarter. Fisher Asset Management LLC now owns 377,694 shares of the medical instruments supplier's stock valued at $98,605,000 after buying an additional 26,594 shares in the last quarter.

Remove Ads

Analyst Ratings Changes

PODD has been the topic of a number of research reports. Royal Bank of Canada initiated coverage on Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective on the stock. Wells Fargo & Company increased their price target on Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Stifel Nicolaus lifted their price objective on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. StockNews.com cut Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Finally, TD Cowen raised their price target on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, January 3rd. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average target price of $292.06.

Insulet Stock Up 1.1 %

NASDAQ PODD traded up $2.82 during trading hours on Wednesday, hitting $266.00. The company's stock had a trading volume of 240,931 shares, compared to its average volume of 715,836. The company has a market capitalization of $18.68 billion, a PE ratio of 45.82, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The company's 50-day simple moving average is $271.17 and its two-hundred day simple moving average is $259.40.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Research analysts anticipate that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Transactions at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares of the company's stock, valued at $888,525. This represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares of the company's stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company's stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.